Potential Applications of Nanotechnology in Urological Cancer

He, Minghui; Chen, Li; Zheng, Ting; Tu, Yu Hsuan; He, Qian; Fu, Hualin; Lin, Johnson; Zhang, Wei; Shu, Gang; He, Lili; Yuan, Zhixiang

doi:10.3389/fphar.2018.00745

Cited by 26 publications

(14 citation statements)

References 124 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the fact that rutin's mode of action is not totally comprehended, this study clearly suggests the possible applicability of rutin for renal cancer treatment. Furthermore, considering this applicability, the encapsulation in nanoparticles could be a relevant strategy to enhance therapeutic efficiency [44]. Nonetheless, the low aqueous solubility of rutin represents an impairment for this incorporation in drug delivery systems.…”

Section: Discussionmentioning

confidence: 99%

Anticancer Activity of Rutin and Its Combination with Ionic Liquids on Renal Cells

et al. 2020

View full text Add to dashboard Cite

The renal cell carcinoma (RCC) is the most common type of kidney cancer. Identifying novel and more effective therapies, while minimizing toxicity, continues to be fundamental in curtailing RCC. Rutin, a bioflavonoid widely found in nature, has shown promising anticancer properties, but with limited applicability due to its poor water solubility and pharmacokinetics. Thus, the potential anticancer effects of rutin toward a human renal cancer cell line (786-O), while considering its safety in Vero kidney cells, was assessed, as well as the applicability of ionic liquids (ILs) to improve drug delivery. Rutin (up to 50 µM) did not show relevant cytotoxic effects in Vero cells. However, in 786-O cells, a significant decrease in cell viability was already observed at 50 µM. Moreover, exposure to rutin caused a significant increase in the sub-G1 population of 786-O cells, reinforcing the possible anticancer activity of this biomolecule. Two choline-amino acid ILs, at non-toxic concentrations, enhanced rutin’s solubility/loading while allowing the maintenance of rutin’s anticancer effects. Globally, our findings suggest that rutin may have a beneficial impact against RCC and that its combination with ILs ensures that this poorly soluble drug is successfully incorporated into ILs–nanoparticles hybrid systems, allowing controlled drug delivery.

show abstract

Section: Discussionmentioning

confidence: 99%

Anticancer Activity of Rutin and Its Combination with Ionic Liquids on Renal Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…NPs are also utilized as a drug delivery system (DD) to increase effects and interactions between drugs and the urothelium. Furthermore, nanotechnology can also associate with other modern technologies to advance enhance effectively [ 113 ]. In this review, we intend to focus on nanotechnologies with potential and useful applications in BC treatment, also we will investigate several nanomaterials as nanocarriers to reduce side effects and enhance the effect of chemotherapy drugs to improve treatment of BC.…”

Section: Applications Of Nanomaterials In Treatment Of Bcmentioning

confidence: 99%

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Barani

Hosseinikhah

Rahdar

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumor cells mostly cause tumor recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumor therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In order to reduce this challenge, anti-cancer drugs can be loaded into NPs that can improve water solubility. In our review, we state several nanosystem, which can effective and useful for the diagnosis, treatment of BC. We investigate the function of metal NPs, polymeric NPs, liposomes, and exosomes accompanied therapeutic agents for BC Therapy, and then focused on the potential of nanotechnology to improve conventional approaches in sensing.

show abstract

“…Some metallic nanoparticles, i.e., gold nanoparticles can be a wonder source of PAI, based on the mechanistic approach of surface plasmon resonance to enhance the absorption. Similarly, the detection of prostate cancer via nanotechnology at a molecular level can be accompanied through prostate-specific antigen (PSA) as they are potential nanoparticle targets [ 75 ].…”

Section: Introductionmentioning

confidence: 99%

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

et al. 2020

View full text Add to dashboard Cite

The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.

show abstract

Potential Applications of Nanotechnology in Urological Cancer

Cited by 26 publications

References 124 publications

Anticancer Activity of Rutin and Its Combination with Ionic Liquids on Renal Cells

Anticancer Activity of Rutin and Its Combination with Ionic Liquids on Renal Cells

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

Contact Info

Product

Resources

About